2,992
回編集
差分
ナビゲーションに移動
検索に移動
→Effectiveness of pneumococcal vaccines
*first reported in late 1960s
==vaccineVaccine==
*PPSV does not induce T-cell dependent immunity
*PCV induces T-cell dependent immunity
**serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 23F
*the reason why PCV13 for older population failed to show persistent efficacy against IPD in the U.S. may be contributed by spread of PCV13 for children which has caused serotype substitutions in community
===History of Pneumococcal vaccines in Japan===
{|class="wikitable"
|+''Table updated on 25th Aug 2023''
|-
!style="width:4em" rowspan="2"|Year
!style="width:12em"|PPSV23
!style="width:12em"|PCV7
!style="width:12em"|PCV13
!style="width:12em"|PCV15
!style="width:12em"|PCV20
|-
!Pneumovax NP||Prevenar||Prevenar13||Vaxneuvance||
|-
!1988<br>昭和63
|'''Approved'''<br>- 2yr≤<br>'''''Covered by Public Health Insurance'''''<br>- Asplenia|| || || || |
|-
!2009<br>平成21
| ||'''Approved'''<br>- 2mo≤ ≤9yr|| || ||
|-
!2010<br>平成22
| ||'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr)|| || ||
|-
!2013<br>平成25
| ||'''Terminated''' and switched to PCV13||'''Approved'''<br>- 2mo≤ <6yr<br>'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr)|| ||
|-
!2014<br>平成26
|'''''Routinized'''''<br>- at 65yr<br>- 60-64yr with specific chronic conditions|| ||'''Approved'''<br>- 65yr≤ at risk of IPD|| ||
|-
!2020<br>令和2
| || ||'''Approved'''<br>- 6yr≤ at risk of IPD|| ||
|-
!2022<br>令和4
| || || ||'''Approved'''<br>- elderly<br>- adults at risk of IPD||
|-
!2023<br>令和5
| || || ||'''Approved'''<br>- 2mo≤||''Submitted for approval''
|-
! !!PPSV23!!PCV7!!PCV13!!PCV15!!PCV20
|}
===Efficacy of pneumococcal vaccines===
===Effectiveness of pneumococcal vaccines===
===Effectiveness against colonization===
==Serotype replacement==
==Overwhelming Post-Splenectomy Infection (OPSI) and pnuemococcus==
